[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368743-105":59,"doc-detail-368743-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","atovaquone-proguanil-and-reduced-digestive-cancer-risk-a-toxoplasma-gondii-connection","Atovaquone-proguanil and reduced digestive cancer risk - a Toxoplasma gondii connection","","Emerging evidence suggests microbial pathogens contribute to digestive cancer risk. Atovaquone–proguanil (A-P), an antimalarial with antiparasitic activity, has been associated with a reduced risk of colorectal cancer (CRC). A retrospective cohort study using the TriNetX US Collaborative Network examined over 100,000 individuals aged 40–69 matched 1:1 to controls on other medications, with incident digestive cancers analyzed via Cox proportional hazards models. A metagenomic analysis of 1,044 fecal samples assessed Toxoplasma gondii abundance in CRC-associated microbiota. A-P use correlated with lower digestive cancer incidence across all age groups (HR 0.49–0.53, all p \u003C 0.001), extending to pancreatic cancer (HR 0.50–0.72). T. gondii was the most discriminatory species for CRC, detected above threshold in 22.6% of CRC samples versus 1.6% of controls (OR 18.2, p = 2.3 × 10−22). Findings suggest T. gondii may be an overlooked microbial risk factor and that A-P could provide chemopreventive effects through antiparasitic activity; prospective studies are needed to evaluate prevention potential.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/atovaquone-proguanil-and-reduced-digestive-cancer-risk-a-toxoplasma-gondii-connection/368743/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/atovaquone-proguanil-and-reduced-digestive-cancer-risk-a-toxoplasma-gondii-connection/368743.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What study design was used to evaluate atovaquone-proguanil (A-P) and digestive cancer risk?","Question",{"text":112,"@type":113},"A retrospective cohort analysis used the TriNetX US Collaborative Network, matching A-P users 1:1 to controls who received other medications, and analyzed incident digestive cancers with Cox proportional hazards models.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the role of Toxoplasma gondii investigated?",{"text":117,"@type":113},"A metagenomic analysis assessed Toxoplasma gondii abundance in fecal samples from individuals with CRC-associated microbiota, comparing CRC cases to controls.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main results linking A-P and cancer outcomes?",{"text":121,"@type":113},"A-P use was associated with a significant reduction in digestive cancer incidence across age groups (HR 0.49–0.53) and also showed protective associations for pancreatic cancer (HR 0.50–0.72).",{"name":123,"@type":110,"acceptedAnswer":124},"Why do the authors suggest Toxoplasma gondii could be a microbial risk factor?",{"text":125,"@type":113},"T. gondii can colonize the intestinal epithelium, persist in tissue cysts, induce chronic low-grade inflammation, disrupt epithelial barrier integrity, and create a pro-oncogenic environment; the study found T. gondii strongly discriminated CRC-related microbiota.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368743,1790808148,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","RESEARCH LETTER     \nAtovaquone-proguanil and reduced digestive cancer risk: a Toxoplasma gondii connection  \nAriel Israel a,b, Sarah Israel c, Abraham Weizman d, Shai Ashkenazi e,f, Shlomo Vinker a, Eli Magen g, and Eugene Merzon a,e  \naLeumit Research Institute, Leumit Health Services, Tel Aviv, Israel; bDepartment of Epidemiology and Preventive Medicine, School of Public Health, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; cDepartment of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; dResearch Unit, Geha Mental Health Center, Felsenstein Medical Research Center, and Sagol School of Neurosciences, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; eAdelson School of Medicine, Ariel University, Ariel, Israel; fUnit of Infectious Diseases, Schneider Children’s Medical Center, Petah Tikva, Israel; gMedicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, Ashdod, Israel  \nABSTRACT  \nEmerging evidence suggests microbial pathogens contribute to digestive cancer risk. Atovaquone – proguanil (A-P), an antimalarial with antiparasitic activity, has been associated with a reduced risk of colorectal cancer (CRC) . We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including over 100,000 individuals aged 40–69 years who received A-P, matched 1:1 to controls who received other medications. Incident digestive cancers were analyzed using Cox proportional hazards models. Additionally, we performed a metagenomic analysis of 1,044 fecal samples from 156 individuals to assess the abundance of Toxoplasma gondii in CRC-associated microbiota. A-P use was associated with a significant reduction in digestive cancer incidence across all age groups: hazard ratios (HRs) ranged from 0.49 to 0.53 (all p \u003C 0.001) . Protective associations extended to pancreatic cancer (HR range, 0.50–0.72) . In metagenomic analysis, T. gondii was the most discriminatory microbial species for CRC (p = 1.8 × 10−16), detected above threshold in 22.6% of CRC samples versus 1.6% of controls (odds ratio 18 .2, 95% CI, 8 .2–47.6, p = 2.3 × 10−22) . These findings suggest T. gondii may be an overlooked microbial risk factor for digestive cancers, and that A-P may offer chemopreventive effects through antiparasitic activity. Prospective studies are needed to evaluate its preventive potential.  \nARTICLE HISTORY  \nReceived 8 April 2025 Revised 27 May 2025 Accepted 4 August 2025  \nKEYWORDS  \nColorectal cancer; pancreatic cancer; Toxoplasma gondii; atovaquone; metagenomics; microbiota; cancer prevention; electronic health records  \nIntroduction  \nDigestive tract cancers, including those of the colon, pancreas, and stomach, are among the leading causes of cancer-related deaths worldwide. Colorectal cancer (CRC) alone accounts for over 900,000 deaths annually and remains the second most common cause of cancer mortality globally. 1 While genetic predisposition, inflammation, and environmental exposures contribute to cancer risk, microbial factors have emerged as important but incompletely understood influences on digestive tract carcinogenesis.2  \nBacterial pathogens such as Helicobacter pylori and Fusobacterium nucleatum have been implicated in gastric and colorectal cancers, respectively.3,4 However, most studies of the cancer-associated microbiome have focused on bacteria, often overlooking protozoa, which are typically undetectable by 16S rRNA gene sequencing and often absent from metagenomic reference databases.5,6  \nAtovaquone-proguanil (A-P) is a well-tolerated antimalarial drug combination used primarily for shortterm prophylaxis. In prior observational studies, A-P exposure has been associated with reduced incidence of several cancers.7 Although this has been attributed to its mitochondrial inhibitory effects, such a mechanism does not fully explain the prolonged reduction in can","cbCaiuPj9rxVqDOK","https://ap.wps.com/l/cbCaiuPj9rxVqDOK","pdf",2927010,13,"English","# Abstract\n# Introduction\n## Microbial factors in digestive cancer risk\n## Limitations of current microbiome analyses\n## Rationale for studying atovaquone-proguanil and Toxoplasma gondii","[{\"question\":\"What study design was used to evaluate atovaquone-proguanil (A-P) and digestive cancer risk?\",\"answer\":\"A retrospective cohort analysis used the TriNetX US Collaborative Network, matching A-P users 1:1 to controls who received other medications, and analyzed incident digestive cancers with Cox proportional hazards models.\"},{\"question\":\"How was the role of Toxoplasma gondii investigated?\",\"answer\":\"A metagenomic analysis assessed Toxoplasma gondii abundance in fecal samples from individuals with CRC-associated microbiota, comparing CRC cases to controls.\"},{\"question\":\"What were the main results linking A-P and cancer outcomes?\",\"answer\":\"A-P use was associated with a significant reduction in digestive cancer incidence across age groups (HR 0.49–0.53) and also showed protective associations for pancreatic cancer (HR 0.50–0.72).\"},{\"question\":\"Why do the authors suggest Toxoplasma gondii could be a microbial risk factor?\",\"answer\":\"T. gondii can colonize the intestinal epithelium, persist in tissue cysts, induce chronic low-grade inflammation, disrupt epithelial barrier integrity, and create a pro-oncogenic environment; the study found T. gondii strongly discriminated CRC-related microbiota.\"}]","Atovaquone-proguanil and reduced digestive cancer risk - a Toxoplasma gondii connection | PDF",1790178294,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc459dfb190e8b11f6f8cf2a2e3a9b58.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dba49a20160f706396d6faf4fdf0fccc.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/543e065f8568646ba3e36da9eb5d8e6b.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4466a10b35f85b021f6e174530ae8fc2.webp",980,1306]